Evidence map›Paper›PMID 39469161›Full record

ArticleIndian journal of hematology & blood transfusion : an official journal of Indian Society of Hematology and Blood Transfusion2024

Prognostic Significance of Regulatory T-Cells and PD-1 + CD8 T-Cells in Chronic Myeloid Leukemia Patients Treated with Generic Imatinib.

Fen Saj, Ram Vasudevan Nampoothiri, Deepesh Lad, Aditya Jandial, Man Updesh Singh Sachdeva, Parveen Bose, Neelam Varma, Alka Khadwal, Gaurav Prakash, Pankaj Malhotra

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Indian journal of hematology & blood transfusion : an official journal of Indian Society of Hematology and Blood Transfusion, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed.

  1. Article
  2. Review
  3. Review
  4. Chronic Myeloid Leukemia in Resource Limited Settings: Treatment Free Remission and Tyrosine Kinase Resistance.Indian journal of hematology & blood transfusion : an official journal of Indian Society of Hematology and Blood Transfusion · 2024
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

Fen SajDepartment of Clinical Hematology and Medical Oncology, Postgraduate Institute of Medical Education and Research (PGIMER), Nehru Hospital, Room No 18, 4th Level, F Block, Chandigarh, India.
Ram Vasudevan NampoothiriTransplantation and Cellular Therapy Program, The Ottawa Hospital, University of Ottawa, Ottawa, ON Canada.
Deepesh LadDepartment of Clinical Hematology and Medical Oncology, Postgraduate Institute of Medical Education and Research (PGIMER), Nehru Hospital, Room No 18, 4th Level, F Block, Chandigarh, India.
Aditya JandialDepartment of Clinical Hematology and Medical Oncology, Postgraduate Institute of Medical Education and Research (PGIMER), Nehru Hospital, Room No 18, 4th Level, F Block, Chandigarh, India.
Man Updesh Singh SachdevaDepartment of Clinical Hematology and Medical Oncology, Postgraduate Institute of Medical Education and Research (PGIMER), Nehru Hospital, Room No 18, 4th Level, F Block, Chandigarh, India.
Parveen BoseDepartment of Clinical Hematology and Medical Oncology, Postgraduate Institute of Medical Education and Research (PGIMER), Nehru Hospital, Room No 18, 4th Level, F Block, Chandigarh, India.
Neelam VarmaDepartment of Clinical Hematology and Medical Oncology, Postgraduate Institute of Medical Education and Research (PGIMER), Nehru Hospital, Room No 18, 4th Level, F Block, Chandigarh, India.
Alka KhadwalDepartment of Clinical Hematology and Medical Oncology, Postgraduate Institute of Medical Education and Research (PGIMER), Nehru Hospital, Room No 18, 4th Level, F Block, Chandigarh, India.
Gaurav PrakashDepartment of Clinical Hematology and Medical Oncology, Postgraduate Institute of Medical Education and Research (PGIMER), Nehru Hospital, Room No 18, 4th Level, F Block, Chandigarh, India.
Pankaj MalhotraDepartment of Clinical Hematology and Medical Oncology, Postgraduate Institute of Medical Education and Research (PGIMER), Nehru Hospital, Room No 18, 4th Level, F Block, Chandigarh, India.ORCID 0000-0001-9495-9789

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The impact of T-regulatory cells (Tregs), PD-1 + CD8 T-cells, and their dynamics during treatment with imatinib mesylate remains poorly understood in patients with chronic myeloid leukemia (CML). We conducted a prospective study on newly diagnosed, treatment-naïve adult (> 18 years old) patients with CML in the chronic phase (CP) and age- and sex-matched controls. Peripheral blood samples were collected at diagnosis and after three months of imatinib therapy to assess Tregs and PD-1 + CD8 T-cell levels using flow cytometry. The study comprised 57 patients with a median age of 39 years, including 27 males (47%). At baseline, the mean percentage of Tregs was significantly higher in CML patients (3.6 ± 0.32%) compared to controls (1.58 ± 0.21%) (

Indexed as

CMLImatinibPD1 + CD8 T-cellsT-regulatory cells

Identifiers

PMID39469161
PMCPMC11512970

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.